Porter P L, Malone K E, Heagerty P J, Alexander G M, Gatti L A, Firpo E J, Daling J R, Roberts J M
Program in Cancer Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA.
Nat Med. 1997 Feb;3(2):222-5. doi: 10.1038/nm0297-222.
Mutations in certain genes that regulate the cell cycle, such as p16 and p53, are frequently found in human cancers. However, tumor-specific mutations are uncommon in genes encoding cyclin E and the CDK inhibitor p27Kip1, two cell-cycle regulators that are also thought to contribute to tumor progression. It is now known that levels of both cyclin E and p27 can be controlled by posttranscriptional mechanisms, indicating that expression of these proteins can be altered by means other than simply mutation of their respective genes. Thus, changes in p27 and cyclin E protein levels in tumors might be more common than previously anticipated and may be indicators of tumor behavior.
在某些调控细胞周期的基因中,如p16和p53,其突变在人类癌症中经常被发现。然而,在编码细胞周期蛋白E和CDK抑制剂p27Kip1的基因中,肿瘤特异性突变并不常见,这两种细胞周期调节因子也被认为与肿瘤进展有关。现在已知细胞周期蛋白E和p27的水平都可以通过转录后机制来控制,这表明这些蛋白质的表达可以通过除了简单地突变其各自基因之外的其他方式来改变。因此,肿瘤中p27和细胞周期蛋白E蛋白水平的变化可能比以前预期的更为常见,并且可能是肿瘤行为的指标。